Home » Stocks » Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. (BDTX)

Stock Price: $35.50 USD -2.53 (-6.65%)
Updated Jul 9, 2020 2:25 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.27B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 35.91M
EPS (ttm) -13.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $35.50
Previous Close $38.03
Change ($) -2.53
Change (%) -6.65%
Day's Open 38.11
Day's Range 35.05 - 38.11
Day's Volume 182,837
52-Week Range 17.63 - 46.25

More Stats

Market Cap 1.27B
Enterprise Value 917.82M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 35.91M
Float 15.84M
EPS (basic) n/a
EPS (diluted) -13.87
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.83M
Short Ratio 29.29
Short % of Float 11.80%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.35
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 357.01M
Net Cash / Share 9.94
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -17.45%
ROE -21.76%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$49.00*
(38.03% upside)
Low
42.0
Current: 35.50
High
53.0
Target: 49.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-29.33-8.90-4.12
Net Income-35.26-8.93-4.60
Shares Outstanding2.082.021.92
Earnings Per Share-16.99-4.42-2.39
Operating Cash Flow-24.67-8.45-2.35
Capital Expenditures-0.02-0.08-0.08
Free Cash Flow-24.70-8.53-2.43
Cash & Equivalents15551.667.88
Net Cash / Debt15551.667.88
Assets15851.838.02
Liabilities4.886.602.24
Book Value-47.16-15.54-6.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Black Diamond Therapeutics, Inc.
Country United States
Employees 37
CEO David M. Epstein

Stock Information

Ticker Symbol BDTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BDTX

Description

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.